Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar helpmesav (< 20) Submitted: 12/31/2011 12:32:50 PM : Outperform Start Price: $3.37 DVAX Score: +4.61

Heplisav will be approved last quarter 2012 and their pipleine is strong

Featured Broker Partners


Advertisement